You are here

Fast Track Status Granted to TTS CD3 for the Treatment of Non-Small Cell Lung Cancer

LUND, Sweden, Dec. 1 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted fast track status to Active Biotech's candidate drug TTS CD3 for the treatment of non-small cell lung cancer.

FDA's fast track program is designed to facilitate the development of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address important unmet medical needs.

Currently, a Phase I clinical study with TTS CD3 is under way and the Phase II/III clinical program is planned to start during 2005. This time plan is dependent of the length of the ongoing dose-escalation study, i.e. when a maximal dose is obtained.

In parallel with the ongoing Phase I studies, Active Biotech intends to start a clinical study to examine the safety of TTS CD3 in combination with established chemotherapies of non- small cell lung cancer.

Source: Active Biotech AB

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds